ダウンロード数: 437
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
s11748-009-0440-2.pdf | 110.23 kB | Adobe PDF | 見る/開く |
タイトル: | Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. |
著者: | Okubo, Kenichi Sonobe, Makoto Fujinaga, Takuji Shoji, Tsuyoshi Sakai, Hiroaki Miyahara, Ryo Bando, Toru Date, Hiroshi Shibuya, Keiko Hiraoka, Masahiro |
著者名の別形: | 大久保, 憲一 |
キーワード: | Chemotherapy Extrapleural pneumonectomy Malignant pleural mesothelioma Radiation therapy Trimodality therapy |
発行日: | Nov-2009 |
出版者: | Springer Verlag |
誌名: | General thoracic and cardiovascular surgery |
巻: | 57 |
号: | 11 |
開始ページ: | 585 |
終了ページ: | 590 |
抄録: | PURPOSE: Multimodality therapy has been applied to resectable malignant pleural mesothelioma, but the tolerability of the treatment and relapse pattern in detail remain unknown. We reviewed our experience of trimodality therapy as a single-institution study in Japan. METHODS: A total of 16 patients with resectable malignant pleural mesothelioma were intended to treat with extra-pleural pneumonectomy followed by platinum-based chemotherapy and external beam radiation therapy. The histology of the tumors was epithelioid in 10, sarcomatoid in 4, and biphasic in 2. International Mesothelioma Interest Group staging was stage II in 1, stage III in 11, and stage IV in 4. The tolerability to the combined treatment, the survival, and the relapse pattern were examined. RESULTS: All patients underwent a macroscopic complete resection. In all, 14 patients received chemotherapy, and subsequently 13 underwent radiotherapy, indicating a tolerability of 81%. The overall median survival was 28.1 months; and the 2-year and 5-year survival rates were 53.3% and 26.7%, respectively. In patients with stage III or lower disease, the median survival was 37.9 months. Recurrence was seen in eight patients; the first relapse site was local in seven and distant in two. The local recurrences occurred within 24 months, mostly around 12 months, after the extrapleural pneumonectomy, whereas the distant metastases occurred later. CONCLUSION: Trimodality therapy showed a survival benefit in patients with stage III or lower malignant pleural mesothelioma. Most of the recurrences were local. Therefore, better local control is required to improve the prognosis of the disease. |
著作権等: | c 2009 The Japanese Association for Thoracic Surgery. This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 |
URI: | http://hdl.handle.net/2433/92978 |
DOI(出版社版): | 10.1007/s11748-009-0440-2 |
PubMed ID: | 19908112 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。